© 1985 Oxford University Press
research-article |
Absence of Mutagenic Activity for Monosodium Cyanurate1,2



*Monsanlo Company St. Louis, Missouri 63167
Olin Corporation New Haven, Connecticut 06511
ICI Americas, Inc. Wilmington, Delaware 19897
FMC Corporation Princeton, New Jersey 08540
Absence of Mutagenic Activity for Monosodium Cyanurate. HAMMOND, B. G., BARBEE, S. J., WHEELER, A. G., AND CASCIERI, T. (1985). Fundam. Appl. Toxicol. 5, 655664. The mutagenic potential of monosodium cyanurate was evaluated using in vitro and in vivo tests. All in vitro tests were carried out in the presence and absence of metabolic activation. In each assay, the highest concentration tested generally exceeded the solubility of monosodium cyanurate in the incubation medium. In the Salmonella microbial assay, monosodium cyanurate was not mutagenic towards test strains TA 98, 100, 1535, and 1537 up to a concentration of 10,000 µg/plate. Monosodium cyanurate did not induce forward mutations at the TK. locus of L5I78Y mouse lymphoma cells up to a concentration of 2000 µg/ml. No significant increases in sister chromatid exchanges were observed when monosodium cyanurate was incubated with Chinese hamster ovary cells at concentrations up to 1500 µg/ml. In an in vivo test, rats were administered monosodium cyanurate by gavage at single dosages up to 5000 mg/kg and killed 24 and 48 hr after dosing. Bone marrow cells were collected and examined for chromosomal aberrations. At the time points examined, there was no evidence of monosodium cyanurate-induced chromosomal aberrations in rat bone marrow cells